In short
A new drug called AMY109 is being studied in clinical trials to treat endometriosis, a painful condition affecting women. This article explores the ongoing research into AMY109's effectiveness and safety for managing endometriosis symptoms and its potential to improve the lives of those living with this condition.
At a glance
- Study Type
- Phase II, randomized, double-blind
- Drug Studied
- AMY109 (alone and with desogestrel)
- Condition
- Endometriosis
- Main Objective
- Evaluate efficacy and safety of AMY109
- Primary Endpoints
- Changes in r-ASRM score and endometriotic nodule size
- Eligibility Age
- 18-49 years
- Key Inclusion Criteria
- Moderate to severe endometriosis-related pain
- Study Cohorts
- Laparoscopy (UK), Imaging (EU)
- AMY109 Administration
- Intravenous infusion
- Maximum Treatment Period
- 52 weeks
What is AMY109?
AMY109 is a new medication currently being studied for the treatment of endometriosis, a painful condition affecting many women. It is classified as an investigational drug, which means it is still undergoing clinical trials to determine its effectiveness and safety.
How AMY109 Works
While the exact mechanism of AMY109 is not fully described in the available information, it is known to be a type of antibody preparation. Antibodies are proteins that can target specific substances in the body. In this case, AMY109 appears to target a substance called IL-8 (Interleukin-8), which may play a role in the development or progression of endometriosis.
Target Condition: Endometriosis
Endometriosis is a condition where tissue similar to the lining of the uterus grows outside the uterus. This can cause severe pain, especially during menstruation (dysmenorrhea) and sexual intercourse (dyspareunia). It can also lead to chronic pelvic pain, known as non-menstrual pelvic pain (NMPP). AMY109 is being studied to see if it can help reduce these symptoms and improve the quality of life for women with endometriosis.
Clinical Trial Details
The clinical trial for AMY109 is a Phase II study, which means it's testing the drug's effectiveness and safety in a larger group of people after initial safety studies have been completed. The study is described as randomized and double-blind, which are important features that help ensure the results are reliable.
The main goals of the study are:
- To evaluate how well AMY109 works compared to a drug called desogestrel
- To assess the effectiveness of AMY109 when used in combination with desogestrel
- To measure changes in endometriosis severity using laparoscopy (a type of minimally invasive surgery) and magnetic resonance imaging (MRI)
Eligibility Criteria
To participate in the AMY109 clinical trial, patients must meet certain criteria. Some key requirements include:
- Being a woman between 18 and 49 years old
- Having moderate to severe endometriosis-related pain, including:
- Non-menstrual pelvic pain (NMPP): A pain score of 4 or higher on at least 4 days during the screening period
- Dysmenorrhea (painful periods): A pain score of 4 or higher on at least 2 days during the screening period
- For some participants, having a confirmed diagnosis of stage III or IV endometriosis based on a previous laparoscopy
- For others, having at least one ovarian endometrioma (a type of cyst) or endometriotic nodule visible on MRI
Exclusion Criteria
Certain factors may prevent participation in the trial. These include:
- Significant abnormalities in laboratory tests or physical examinations
- Chronic pelvic pain not caused by endometriosis
- Previous hysterectomy (removal of the uterus) or removal of both ovaries
- Recent treatment with other antibody medications
- Previous treatment with anti-IL-8 antibodies
Potential Benefits
While the effectiveness of AMY109 is still being studied, the researchers hope it may offer several potential benefits for women with endometriosis:
- Reduction in pain associated with endometriosis, including non-menstrual pelvic pain and painful periods
- Improvement in the appearance of endometriosis lesions as seen on laparoscopy or MRI
- Potential alternative or addition to current treatments for endometriosis
Administration and Dosage
AMY109 is administered as a solution for injection through intravenous infusion. This means it's given directly into a vein. The maximum daily dose being studied is 10 mg/kg (milligrams per kilogram of body weight), with a maximum total dose of 130 mg/kg over the course of treatment. The treatment period may last up to 52 weeks (1 year).